ArticleAdvanced healthcare materials2025
3D Differentiation of Bone-Marrow Derived Mesenchymal Stromal Cells into the Keratocyte Lineage for Corneal Bioprinting.
Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Revolutionizing vision using corneal 3D printing.Trends in biotechnology · 2026Review
- Toward clinically relevant automated corneal biomanufacturing with human-derived FBS alternatives.Scientific reports · 2026Article
- 3D Differentiation of Bone-Marrow Derived Mesenchymal Stromal Cells into the Keratocyte Lineage for Corneal Bioprinting.Advanced healthcare materials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Corneal stromal keratocytes (CSK) play a critical role in maintaining corneal transparency and biomechanical integrity. However, challenges in obtaining enough functional CSK limit the progress of corneal tissue engineering and bioprinting. This study presents a novel protocol for the differentiation of bone marrow-derived mesenchymal stromal cells (BM-MSC) into CSK-like cells, optimized for both 2D and 3D culture systems, including 3D bioprinted constructs. A key innovation of this work is the preconditioning of BM-MSC on collagen-coated plates to reduce α-SMA expression, a marker associated with myofibroblast differentiation and fibrosis. Immunofluorescence and qPCR analyses demonstrated significant upregulation of CSK-specific markers, including Lumican, Keratocan, ALDH1A1, ALDH3A1, and Collagen I, while α-SMA expression remained undetectable. Notably, 3D cultures provided an enhanced environment for CSK differentiation, mimicking the corneal stroma more closely than 2D cell culture systems. The combination of preconditioning and 3D culture systems offers a promising approach for the biofabrication of functional corneal stroma, paving the way for future therapies aimed at treating corneal opacity and scarring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.